New research published in the journal Neuro-Oncology reveals significant findings that could lead to improved treatment for children with Group 3 medulloblastoma brain tumors. These studies, part of the £5 million INSTINCT research program led by Professor Steve Clifford, identified key genetic defects and targeted approaches to treating these aggressive and often incurable tumors. The research showed variations in clinical outcomes within the MYC-amplified tumors, leading to the identification of specific groups of patients who urgently require new treatment approaches. The findings also suggest targeting the serine/glycine synthesis pathway with PHGDH inhibitor drugs as a potential new treatment strategy. Funding for the studies came from several organizations, including Children with Cancer UK, Cancer Research UK, The Brain Tumor Charity, and others. The research represents a significant step towards more effective and targeted treatments for pediatric brain cancer, particularly high-risk medulloblastomas.
Source link
Major studies reveal improved treatment for children with Group 3 medulloblastoma
